Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date: April 25, 2017
Context: The filing serves as a Regulation FD disclosure to provide an update on the top-line six-month results from the Company's randomized Phase I/II HOPE clinical trial. The detailed results were presented via a slide deck attached as Exhibit 99.1.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is strictly a disclosure of clinical trial updates and does not report on the Company's financial performance for any period.
Material Changes
The material change disclosed is the release of top-line six-month results from the HOPE clinical trial. No financial changes or operational shifts regarding revenue or expenses are reported in this specific document.
Guidance, Outlook, and Risks
Management Commentary: The Company provided an update on clinical trial results via a slide presentation available on its investor website and attached to this filing.
Legal Disclaimer: The information contained in this Form 8-K and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. It is not subject to the liabilities of that section and shall not be incorporated by reference into any filing under the Securities Act or Exchange Act, except as expressly set forth by specific reference.
Investor Verification Checklist
- Verify the specific clinical data points in the slide presentation (Exhibit 99.1) attached to this filing.
- Confirm the status of the HOPE clinical trial on the Company's official investor website (www.capricor.com).
- Note that this filing does not include audited financial data; refer to the most recent 10-K or 10-Q for financial metrics.
- Review the legal disclaimer regarding the non-filing status of the clinical data for liability purposes.